金活医药集团(01110.HK)订立独家分销协议推广马来酸依那普利叶酸片
格隆汇10月3日丨金活医药集团(01110.HK)公告,于2020年10月30日,公司全资附属公司深圳市金活医药有限公司与深圳奥萨制药有限公司订立独家分销协议,内容有关在中国内地市场推广及分销10.4毫克马来酸依那普利叶酸片。
根据该协议,奥萨已委任深圳金活为其在中国内地推广、销售及分销该产品的独家分销商,为期五年。初始五年期限届满后,该协议可自动续期五年。通过战略性地利用其市场网络,公司旨在于中国内地的高血压药物市场上建立该产品的强大地位。
根据奥萨提供的资料,马来酸依那普利叶酸片是一种专为有效控制H型高血压而设计的多风险因素控制性创新预防复合处方药。该产品已被归类为国家一类新药(化学药品)并被纳入中国国家基本医疗保险、工伤保险和生育保险药品目录(2009)。
奥萨为一家致力于医疗及诊断产品的研发及商业化的制药公司,其总部位于中国广东省深圳市。
公司表示,通过利用其商业平台、广泛的分销网络和丰富的营销策略,集团的目标为令该产品的价值及市场潜力最大化,并为广大的H型高血压患者提供服务。董事会认为,订立该协议将进一步扩大集团的产品组合及充分利用于蓬勃发展的中国市场中消费者对医药产品不断增长的需求,从而巩固其市场地位,此举将对集团及公司股东整体有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.